|
UNKNOWN PRIMARY: ADENOCARCINOMA
|
||||||
|
Regimen/Number Of Patients |
Drug Dose and Route |
Leukopenia/ Neutropenia Toxicity |
Anemia Toxicity |
Other Grade III-IV Toxicities |
Emetogenic Potential |
Consequences of Adverse Event(s) |
|
FAM (Goldberg RM, et al. J Clin Oncol 1986;4:395-99)
N= 43
|
5 – Fluorouracil 600mg/m2 IV days 1, 8, 29, 36 Doxorubicin 30 mg/m2 IV days 1, 29 Mitomycin 10 mg/m2 IV day 1 Repeat cycle every 8 weeks |
Leukopenia Grade III-IV 7%
|
|
Neutropenic Sepsis 5 % Thrombocytopenia 12 % Mucositis (Grade II-III) 7%
|
Day 1 – Leve 4 Day 8 – Level 2 Day 29 – Level 4 Day 36 – Level 2 |
Infection mortality 2% Cardiac mortality 2 %
|
|
Gemcitabine Carboplatin Paclitaxel (Greco FA, et al, J Clin Oncol, 2002;20:1651-56)
N= 120
|
Gemcitabine 1000 mg/m2 IV days 1, 8 Carboplatin targeted by the Calvert equation to AUC of 5, day 1 Paclitaxel 200 mg/m2 IV over 1 hour day 1 Repeat cycle every 21 days Appropriate premedications listed in Seciton 2, Commonly Used Premedicaiton Regimens
|
Leukopenia Grade III 28 % Grade IV 4 %
|
GradeIII-IV 10% |
Fevrile Neutropenia 10 % Thrombocytopenia 14% Fatigue 18 % Arthralgia 7 % Peripheral Neutropathy 7 % Nausea / Vomiting 6% Hypersensitivity 2 % |
Day 1 – Level 5 Day 8 – Level 2 |
1 treatment-related death due to sepsis
|
|
Paclitaxel Carboplatin Etoposide (hainsworth JD, et al. J Clin Oncol 1997;15:2385-93)
N= 55
|
Paclitaxel 200 mg/m2 IV over1 hour, day 1, followed by Carboplatin dose targeted by Calvert equation to AUC of 6 IV day 1 Etoposide 50 mg/ d PO alternated with 100 mg/d PO days 1 – 10 Repeat cycle every 21 days Appropriate premedications listed in Section2, Commonly Used Premedication Regimens |
Leukopenia Grade III 56% Grade IV 20 5
|
|
Nausea/Vomiting 9 % Thrombocytopenia 26% Peripheral neuropathy (Grade III) 7 % Hypersensitivity (Grade IV ) 2 % Fatigue ( Grade III) 7 % Arthralgia/Myalgia (Grade III) 2 %
|
Day 1 – Level 5 Days 2 -10- Level 2 |
Discontinued treatment 4 % Decreased dose 40 % RBC transfusion 38 % Hospitalization for febrile neutropenia 13 % |